Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP-001 following thermal ablation in advanced solid tumors
NCT05688280Phase 2Active, not recruiting
- Sponsor
- Immunophotonics
- Start
- Nov 2022
- Primary completion
- Feb 2025
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 2 trial of IP-001 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), soft tissue sarcoma (STS), sponsored by Immunophotonics. Started Nov 2022; status: active, not recruiting.
02
Drugs
IP-001
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05688280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688280.